Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 668.95M +250.8% |
| Revenue (ttm) | n/a |
| Net Income | -65.58M |
| EPS | -1.45 |
| Shares Out | 65.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,024 |
| Open | 9.79 |
| Previous Close | 9.70 |
| Day's Range | 9.70 - 10.24 |
| 52-Week Range | 5.20 - 12.86 |
| Beta | 1.42 |
| Analysts | Strong Buy |
| Price Target | 16.00 (+56.25%) |
| Earnings Date | Aug 10, 2026 |
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company’s product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the ... [Read more]
News
Eupraxia Pharmaceuticals initiated with a Buy at Stifel
Stifel initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $25 price target Eupraxia is validating its Diffusphere platform starting with a well-known corticosteroid, fluticaso...
Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year
The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the end of the…
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indicat...
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
EoEHSS (EoE Histology Scoring System) is a standardized method used to monitor esophageal tissue damage in EoE patients. Sub scores of EoEHSS are reported to specifically evaluate the tissue inflammat...
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)
EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data ...
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
Eupraxia Pharmaceuticals (EPRX) announced the appointment of Dr. Jeymi Tambiah as Chief Medical Officer as well as the retirement of Dr. Mark Kowalski, Eupraxia’s current CMO. Dr. Jeymi Tambiah is
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer
VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ...
Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial
Eupraxia Pharmaceuticals (EPRX) announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the Resolve trial evaluating EP-104GI for
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair on Monday initiated coverage on Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), a clinical-stage biotechnology company focused on the development of locally delivered, extended-release pro...
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
William Blair initiated coverage of Eupraxia Pharmaceuticals (EPRX) with an Outperform rating and $14 fair value estimate. Eupraxia is a clinical-stage biotechnology company developing extended-releas...
Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
Eupraxia Pharmaceuticals (EPRX) announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatme...
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes lowered the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $11 from $12 and keeps a Buy rating on the shares. The firm adjusted the
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i...
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00
Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the offering.
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
VICTORIA, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals announces common shares offering, no amount given
Eupraxia Pharmaceuticals (EPRX) announced the company has filed a preliminary prospectus supplement to its short form base shelf prospectus dated February 5, 2024 in connection with a proposed public ...
Eupraxia Pharmaceuticals Announces Proposed Public Offering
VICTORIA, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging it...
Eupraxia Pharmaceuticals management to meet with Cantor
Meeting to be held in New York on February 2-6 hosted by Cantor.
Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Eupraxia Pharmaceuticals (EPRX) to $19 from $11 and keeps an Overweight rating on the shares. Eupraxia was named a top pick by
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
Eupraxia Pharmaceuticals (EPRX) announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic e...
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improve
Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
Eupraxia Pharmaceuticals (EPRX) announced the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophi...
Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI
The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far...